Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05411614 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hybrid Ablation of Atrial Fibrillation in Heart Failure

Study acronym: HALT AF
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 28, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: May 1, 2022 to Jun 25, 2022
    • Study sites: 6 to 7
    • Study description expanded, about 3 words
    v5
  2. Primary completion date: May 2025 to May 2026v4 Show 5 more changesShow less
    • Enrollment target: 100 to 120
    • Study sites: 1 to 6
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: details revised at 1 of 9 entries
    • Study title expanded, about 3 words
  3. Re-verified, no change to tracked fieldsv3
  4. Secondary endpoints: 10 to 9
    • Study description expanded, about 4 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A randomised controlled trial to assess the efficacy of staged hybrid ablation when compared with standard catheter ablation in patients with non-paroxysmal atrial fibrillation (AF) and Heart Failure
Trial Details
NCT Number NCT05411614
Lead Sponsor St. George's Hospital, London
Conditions
(from sponsor)		 Persistent Atrial Fibrillation, Atrial Fibrillation, Persistent, Atrial Arrhythmia, Atrial Fibrillation, Heart Failure, Left Ventricular (LV) Systolic Dysfunction
Related terms Atrial Fibrillation, Heart Failure
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov